Here’s why Citi says crypto prices have been weak recently
MIAMI BEACH - Oracle Health and Life Sciences and the Cancer Center Informatics Society (Ci4CC) announced Friday a non-binding agreement to collaborate on advancing artificial intelligence innovation in oncology care and research. Oracle (NYSE:ORCL), with a substantial market capitalization of $671.45 billion and annual revenue of $59.02 billion, is a prominent player in the Software industry according to InvestingPro data.
The strategic partnership aims to combine Oracle’s technology with Ci4CC’s national network of NCI-Designated and Community Care Cancer Centers to develop initiatives across several areas of oncology. According to the press release, these initiatives include integrating clinical and genomic data for personalized medicine, developing AI-driven approaches for clinical trials, establishing real-world evidence frameworks, and advancing precision oncology platforms.
"Cancer remains a leading cause of death worldwide, but AI and data science have become powerful allies in the fight," said Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences.
The collaboration also plans to focus on designing an electronic health record system optimized specifically for cancer care.
Sorena Nadaf-Rahrov, President and CEO of the Cancer Center Informatics Society, described the alliance as "a significant milestone" for Ci4CC and its mission to further cancer informatics.
"By integrating Oracle’s cutting-edge and AI-enabled technology with real-world data from our national network of NCI-Designated and Community Cancer Centers, we hope to incubate and operationalize initiatives that will redefine cancer research and patient care," Nadaf-Rahrov said.
The announcement was made during the 24th Cancer Center Informatics Society Symposium. Oracle (NYSE:ORCL) is a provider of integrated applications and infrastructure solutions.The company has demonstrated strong financial performance, with 9.67% revenue growth over the last twelve months and a remarkable 63.85% stock price increase over the past six months. However, InvestingPro analysis indicates the stock is currently trading above its Fair Value with a high P/E ratio of 56.76. Investors seeking deeper insights into Oracle’s valuation can access the comprehensive Pro Research Report, available among 1,400+ US equities covered on InvestingPro.
In other recent news, Oracle has announced plans to launch a new platform called Digital Assets Data Nexus, aimed at enabling banks and financial institutions to manage blockchain-based digital assets. This platform will feature advanced technologies such as multi-ledger infrastructure and pre-built tokenization smart contracts. Additionally, UBS has reiterated its Buy rating for Oracle, setting a price target of $380. The analysis by UBS highlighted positive feedback from Oracle’s AI World event, noting an increased interest in Oracle’s platforms among customers and partners.
Oracle is also collaborating with Baylor College of Medicine to advance research on alcohol-related liver disease. This partnership will leverage Oracle Health’s AI data platform to create a large cohort for studying the disease. Meanwhile, credit traders have shown increased interest in Oracle’s credit default swaps, reflecting concerns over the company’s growing investments in AI infrastructure. These developments come as the U.S. Treasury announced China’s approval of the TikTok transfer agreement, with expectations of progress in the coming weeks and months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.